Heterogeneity of human lymphokine (IL‐2)‐activated killer (LAK) precursors and regulation of their LAK induction by blood monocytes
- 15 September 1988
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 42 (3) , 428-434
- https://doi.org/10.1002/ijc.2910420320
Abstract
Highly purified lymphocytes (> 99%) and monocytes (>90%) were isolated by CCE from peripheral blood of healthy donors. Blood lymphocytes were separated by this CCE into 9 subpopulations. The NK activities of these lymphocyte fractions against NK‐sensitive K‐562 cells and their LAK activities against NK cell‐resistant target (Daudi) cells were assayed promptly or after incubation of the fractions for 4 days with or without an optimal concentration of IL‐2. NK and LAK activities were measured by 4‐hr 51Cr‐release assay. On the basis of their NK and LAK activities, these lymphocyte fractions were classified into 3 subpopulations of LAK precursors: one lacking both NK and LAK activities (Fr. 2), one with moderate NK activity but low LAK activity (Fr. 5), and one possessing both NK and LAK activities (Fr. 8). Addition of autologous fresh monocytes to the lymphocyte cultures resulted in a significant increase in induction of LAK activity in Fr. 2 and Fr. 5. This up‐regulation of lymphocytes in Fr. 2 and Fr. 5 by monocytes was confirmed in parallel experiments by measuring the blastogenic response of the lymphocytes to IL‐2. Depletion of lymphocytes in Fr. 8 of CD16+ (Leu‐11+) NK cells resulted in 74% reduction in LAK induction, whereas depletion of mixtures of monocytes and lymphocytes in Fr. 2 of cells reacting with CD3+ (OKT3+) antibody resulted in a 66% reduction in LAK induction. This up‐regulation of LAK cell induction from LAK precursors by monocytes was confirmed using 4 lines of human lung cancer cells as targets for LAK activity. These results clearly indicate that human monocytes may cause up‐regulation of the expression of IL‐2‐in‐duced LAK activity in T cells and in a subpopulation of NK cells.This publication has 30 references indexed in Scilit:
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Role of alveolar macrophages in pulmonary neoplasiasBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1986
- Synergism of recombinant human interferon gamma with liposome‐encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytesInternational Journal of Cancer, 1986
- Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.The Journal of Experimental Medicine, 1986
- Monocyte‐dependent induction of proliferation of human peripheral T cells by recombinant interleukin 2European Journal of Immunology, 1986
- Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.The Journal of Experimental Medicine, 1983
- Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cellsThe Journal of Experimental Medicine, 1983
- Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytesBiochemical and Biophysical Research Communications, 1982
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982